China Resources Double-Crane Pharmaceutical (SHA:600062) posted 2024 net profit attributable to shareholders of 1.63 billion yuan, down 2.6% from 1.67 billion yuan the previous year.
Earnings per share declined to 1.5838 yuan from 1.6306 yuan, according to a filing with the Shanghai bourse.
The company's revenue inched down 0.9% year over year to 11.2 billion yuan from 11.3 billion yuan.
The board declared a cash distribution of 0.371 yuan per share for 2024.
Shares of the company were down 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.